Yadanzioside G is primarily studied for its potential anti-cancer properties, particularly in inhibiting the growth of certain tumor cells. It has shown activity in inducing apoptosis in liver and lung cancer cell lines through modulation of key signaling pathways such as MAPK and PI3K/Akt. Research also suggests it may enhance the sensitivity of multidrug-resistant cancer cells to conventional chemotherapy agents, making it a candidate for adjuvant therapy. Additionally, it exhibits anti-inflammatory effects by suppressing pro-inflammatory cytokine production, which could be beneficial in chronic inflammatory conditions. Most applications remain in the preclinical research stage, with ongoing studies focused on improving bioavailability and targeted delivery.